BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 326,932 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 326,932 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the sale, the chief executive officer now directly owns 5,371,515 shares of the company’s stock, valued at $194,932,279.35. The trade was a 5.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neil Kumar also recently made the following trade(s):

• On Tuesday, November 19th, Neil Kumar sold 27,389 shares of BridgeBio Pharma stock. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49.

BridgeBio Pharma Trading Down 1.3 %

BridgeBio Pharma stock opened at $35.97 on Friday. BridgeBio Pharma, Inc. has a 12 month low of $21.62 and a 12 month high of $41.04. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of -14.93 and a beta of 1.05. The business’s fifty day simple moving average is $29.64 and its two-hundred day simple moving average is $27.10.

Analysts Set New Price Targets

A number of research analysts have commented on BBIO shares. Scotiabank upped their price target on BridgeBio Pharma from $45.00 to $48.00 and gave the company a “sector outperform” rating in a research report on Monday, November 25th. Evercore ISI raised their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Bank of America boosted their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a research report on Monday, December 16th. Finally, Oppenheimer assumed coverage on shares of BridgeBio Pharma in a research report on Thursday, October 3rd. They set a “market perform” rating on the stock. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.08.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds have recently bought and sold shares of the company. Values First Advisors Inc. bought a new stake in BridgeBio Pharma during the 3rd quarter valued at about $57,000. CWM LLC increased its position in shares of BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after acquiring an additional 1,964 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in BridgeBio Pharma by 56.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after acquiring an additional 1,645 shares during the last quarter. Amalgamated Bank lifted its position in BridgeBio Pharma by 24.7% in the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock valued at $123,000 after acquiring an additional 962 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after purchasing an additional 801 shares during the last quarter. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.